ArticleJournal of fluorescence2025
Application of Pirfenidone-loaded Fluorescence Nanoparticles to Inhibit Hepatocellular Carcinoma by Modulating Oxidative Stress.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging nanomedicine for liver diseases treatment.Journal of nanobiotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC), a major cause of cancer-related mortality, is closely associated with oxidative stress-induced cellular damage. To address the limitations of pirfenidone (PFD)-notably its poor bioavailability and lack of tumor specificity-a novel fructose-based fluorescent nanoplatform (1-Fru-2-ATPMS@PFD) was rationally designed and constructed. The system integrates synthetic and natural small molecules with a silane-modified organic framework, offering improved stability, drug-loading capacity, and optical responsiveness. Structural characterizations confirmed successful assembly and PFD encapsulation, while fluorescence measurements revealed distinct ratiometric features suitable for drug sensing. Furthermore, in vitro assays demonstrated effective inhibition of HCC cell proliferation and favorable regulation of oxidative stress biomarkers. These results suggest that 1-Fru-2-ATPMS@PFD holds great potential as a dual-functional material for targeted drug delivery and fluorescence-guided therapeutic monitoring in liver cancer treatment.
Indexed as
Identifiers
40643769What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.